Your session is about to expire
← Back to Search
89Zr Panitumumab PET/CT Imaging for Head and Neck Cancer
Phase 1
Recruiting
Led By Michael Topf, MD
Research Sponsored by Michael Topf
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 7 years
Awards & highlights
Study Summary
This trial seeks to test a new imaging agent to help diagnose spread of head & neck cancer to other parts of the body. Participants will get the agent and then get scans to compare to standard of care imaging.
Who is the study for?
This trial is for adults over 19 with head and neck squamous cell carcinoma, who have indeterminate metastatic lesions as shown by PET/CT scans. They must have a certain level of hemoglobin, kidney function (eGFR), and platelet count. Excluded are those with recent severe heart conditions, renal disease, pulmonary issues, pregnant or breastfeeding women, or allergies to similar drugs.Check my eligibility
What is being tested?
The study tests an imaging agent called 89Zr panitumumab combined with PET/CT scanning to detect the spread of cancer in patients with head and neck squamous cell carcinoma. It aims to see if this new method is more accurate than standard MRI, CT or PET/CT scans in identifying metastases.See study design
What are the potential side effects?
Potential side effects may include reactions related to the infusion of monoclonal antibodies like Panitumumab such as allergic responses. Since it's an imaging test involving radiation exposure from Zirconium Zr 89 Panitumumab there might be risks associated with that as well.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 7 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 7 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Sensitivity of zirconium Zr 89 panitumumab (89Zr-panitumumab
Secondary outcome measures
Sensitivity of 89Zr-panitumumab
Specificity of 89Zr-panitumumab
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (89Zr panitumumab PET/CT)Experimental Treatment5 Interventions
Patients receive panitumumab IV, 89Zr panitumumab IV, and undergo PET/CT on study
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Panitumumab
2020
Completed Phase 3
~6490
Positron Emission Tomography
2008
Completed Phase 2
~2240
Computed Tomography
2017
Completed Phase 2
~2720
Find a Location
Who is running the clinical trial?
Michael TopfLead Sponsor
Michael Topf, MDPrincipal InvestigatorVanderbilt University/Ingram Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have been diagnosed with squamous cell carcinoma in the head or neck.I am 19 years old or older.I am taking medication for heart rhythm problems.I have severe kidney problems or cannot produce urine.I haven't had a heart attack, stroke, severe heart failure, liver disease, or unstable chest pain in the last 6 months.My scans show possible spread of squamous cell carcinoma.I have had interstitial pneumonitis or pulmonary fibrosis.I have been diagnosed with head and neck cancer, regardless of its stage or specific location.
Research Study Groups:
This trial has the following groups:- Group 1: Diagnostic (89Zr panitumumab PET/CT)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Could you please elaborate on the riskiness of 89Zr panitumumab PET/CT for patient safety?
"Due to the limited data surrounding its safety and efficacy, this diagnostic imaging test (89Zr panitumumab PET/CT) only received a score of 1."
Answered by AI
Is enrollment still available for this research project?
"This particular research trial is not presently seeking participants as it was last updated on February 16th 2023. Information available on clinicaltrials.gov indicates that the study was first posted on April 3rd of the same year. That being said, there are 2,644 other investigations searching for volunteers at this moment in time."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger